Molecular Marker for Predicting Treatment Response in Advanced Renal Cell Carcinoma: Does the Promise Fulfill Clinical Need?

Renal cell carcinoma (RCC) is largely diagnosed incidentally on imaging taken for unrelated reasons. The management of localized lesions is primarily extirpative with excellent results. Treatment of advanced RCC has evolved over recent years with the use of targeted therapies such as tyrosine kinase...

Full description

Saved in:
Bibliographic Details
Published in:Current urology reports 2014, Vol.15 (1), p.375-375, Article 375
Main Authors: Garcia-Roig, Michael, Ortiz, Nicolas, Lokeshwar, Vinata
Format: Article
Language:English
Subjects:
Antineoplastic Agents - therapeutic use
Biomarkers, Tumor - metabolism
Carcinoma, Renal Cell - drug therapy
Carcinoma, Renal Cell - metabolism
Carcinoma, Renal Cell - pathology
Humans
Indoles - therapeutic use
Kidney Diseases (G Ciancio
Kidney Neoplasms - drug therapy
Kidney Neoplasms - metabolism
Kidney Neoplasms - pathology
Medicine
Medicine & Public Health
Nephrology
Niacinamide - analogs & derivatives
Niacinamide - therapeutic use
Phenylurea Compounds - therapeutic use
Pyrroles - therapeutic use
Section Editor
Topical Collection on Kidney Diseases
Treatment Outcome
Urology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Renal cell carcinoma (RCC) is largely diagnosed incidentally on imaging taken for unrelated reasons. The management of localized lesions is primarily extirpative with excellent results. Treatment of advanced RCC has evolved over recent years with the use of targeted therapies such as tyrosine kinase inhibitors, mammalian target of rapamycin inhibitors, and antibody-mediated therapies. The treatment response to these targeted therapies is highly variable, with no clear clinical method of identifying patients who will benefit from or not tolerate therapy. The field of molecular markers has evolved significantly in the last decade, with a multitude of markers identified that predict treatment response and drug toxicity. The following review critically evaluates those molecular markers that have been assessed for their utility in predicting treatment response in patients with advanced/metastatic renal cell carcinoma (mRCC). Identifying the ideal treatment for these patients will improve responses to therapy, minimize morbidity, and save significant healthcare dollars.
ISSN:1527-2737
1534-6285
DOI:10.1007/s11934-013-0375-0